CD274 and neoplasm: However, patients with higher PD-L1 CPS (≥10) had a better treatment response compared to those who received paclitaxel (median OS: 10.4 months vs. 8.0 months, HR: 0.64, 95% CI 0.41–1.02), suggesting that the proportion of tumor cells expressing PD-L1 may influence the therapeutic effect of pembrolizumab [75].